More than 8,300 people joined the annual event to raise funds for Bridge of LifeDENVER, Nov. 12, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced the success of its third annual Move It With Purpose (MIWP) event with more than 8,300 participants, including DaVita teammates, friends, family and key members of the kidney care community. The month-long initiative encourages physical activity — whether it's walking, running, swimming, bicycling or other activities — to be ...

DENVER, Nov. 8, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at UBS Global Healthcare Conference 2024 on Tuesday, November 12, 2024 at 12:30 pm PST (3:30 pm EST). To view the live webcast, visit the UBS page here and create a free registration.About DaVita Inc.DaVita (NYSE: DVA) is a health care provider focused on transforming c ...

Core Insights - DaVita's profitability has declined significantly, leading to a more than 10% drop in its stock value following the latest earnings release, contrasting sharply with the S&P 500's minor dip of 0.3% [1] Financial Performance - For Q3, DaVita reported total revenue of $3.26 billion, an increase from $3.12 billion in the same period of 2023, but its non-GAAP net income fell to $222 million ($2.59 per share) from $268 million year-over-year [2] - The revenue slightly exceeded the average analyst estimate of $3.25 billion, but adjusted profitability was below the consensus estimate of $2.72 [3] Management Commentary - Management attributed the revenue increase to higher average reimbursement rates and fluctuations, along with annual rate increases from the federal Medicare program and a rise in hospital inpatient dialysis treatments [3] Future Guidance - For 2024, DaVita projected adjusted per-share earnings between $9.25 and $10.05, with free cash flow expected to range from $950 million to $1.2 billion, compared to $8.47 and nearly $1.24 billion for full-year 2023 [4] Market Reaction - Investors reacted negatively to the earnings miss, reflecting concerns that a specialized healthcare company should demonstrate stronger growth, especially as the U.S. population ages [5]

Core Viewpoint - DaVita Inc. reported a decline in adjusted earnings per share (EPS) for Q3 2024, missing consensus estimates, despite an increase in revenues driven by higher reimbursement rates and other fluctuations [1][2][9][10]. Financial Performance - Adjusted EPS for Q3 2024 was $2.59, down 9.1% year over year, and missed the Zacks Consensus Estimate by 6.2% [1] - GAAP EPS for the quarter was $2.50, reflecting a decline of 4.6% year over year [1] - Revenues reached $3.26 billion, an increase of 4.6% year over year, surpassing the Zacks Consensus Estimate by 1.3% [2] - Gross profit rose 5.5% year over year to $1.11 billion, with a gross margin of 34.1%, expanding by 30 basis points [6] Revenue Breakdown - Dialysis patient service revenues were $3.14 billion, up 6.3% year over year [3] - Other revenues were $125 million, down 26.2% from the previous year [3] Operational Metrics - Total U.S. dialysis treatments for Q3 were 7,350,784, averaging 93,048 per day, which is a sequential decrease of 0.1% [4] - DaVita served approximately 265,400 patients at 3,113 outpatient dialysis centers as of September 30, 2024 [4] Strategic Developments - During Q3 2024, DaVita opened three and closed 15 dialysis centers in the U.S., while also acquiring one and opening four centers outside the U.S. [5] - The company had around 69,500 patients in risk-based integrated care arrangements, representing $5.4 billion in annualized medical spend [5] Margin and Cost Analysis - Adjusted operating profit totaled $718.2 million, reflecting a 6.1% increase from the prior year [6] - General & administrative expenses increased by 4.4% year over year to $393.5 million [6] Financial Position - DaVita ended Q3 2024 with cash and cash equivalents of $1.09 billion, up from $437.2 million at the end of Q2 [7] - Total debt at the end of Q3 was $9.56 billion, compared to $8.99 billion at the end of Q2 [7] - Cumulative net cash provided by operating activities was $1.47 billion, down from $1.57 billion a year ago [7] Future Outlook - DaVita reiterated its adjusted EPS guidance for 2024, projecting a range of $9.25-$10.05, with the Zacks Consensus Estimate at $9.99 [8]

DaVita Inc. (NYSE:DVA) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Nic Eliason - Group Vice President, Investor Relations Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer Conference Call Participants Andrew Mok - Barclays AJ Rice - UBS Pito Chickering - Deutsche Bank Lisa Clive - Bernstein Joanna Gajuk - Bank of America Ryan Langston - TD Cowen Justin Lake - Wolfe Research Operator Good evening. My name is Michelle and I will be your co ...

DaVita HealthCare (DVA) came out with quarterly earnings of $2.59 per share, missing the Zacks Consensus Estimate of $2.76 per share. This compares to earnings of $2.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.16%. A quarter ago, it was expected that this kidney dialysis provider would post earnings of $2.47 per share when it actually produced earnings of $2.59, delivering a surprise of 4.86%.Over the last four quart ...

. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |---------------------------------------------------------------------|-------------------------------------------|-------------------------------| | For the | transition per ...

Contact: Investor Relations DaVita Inc. ir@davita.com DaVita Inc. 3rd Quarter 2024 Results Denver, Colorado, October 29, 2024 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2024. "We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance," said Javier Rodriguez, CEO of DaVita Inc. "And, in light of recent severe storms, I am grateful for the remarkable resilience of ou ...

DENVER, Oct. 29, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2024. "We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance," said Javier Rodriguez, CEO of DaVita Inc. "And, in light of recent severe storms, I am grateful for the remarkable resilience of our patients and our frontline caregivers." Financial and operating highlights for the quart ...

Core Viewpoint - DaVita Inc. is expected to report third-quarter 2024 results on October 29, with revenue estimates at $3.22 billion, reflecting a 3.2% year-over-year increase, while EPS is projected at $2.76, indicating a 3.2% decline from the previous year [1] Financial Performance - In the last reported quarter, DaVita's EPS was $2.59, exceeding the Zacks Consensus Estimate by 4.9%, and the company has consistently outperformed earnings estimates over the past four quarters with an average earnings surprise of 24.2% [1] - Earnings estimates for DaVita's 2024 earnings have remained flat at $9.99 over the past 60 days [2] Revenue Drivers - Continued strength in revenue per treatment (RPT) has been a key contributor to DaVita's performance, supported by improvements in collection capabilities and targeted investments in technology [3][4] - Health plan negotiations have resulted in modestly higher rate increases due to inflation, which is expected to positively impact quarterly revenues [4] - Management anticipates stronger results from the Integrated Kidney Care business in the second half of the year, driven by timing of revenue recognition [4] International Expansion - DaVita has expanded its international operations in Brazil and Colombia, with acquisitions in Ecuador and Chile already closed, likely contributing additional revenues in the third quarter [4][10] Stock Performance - Year-to-date, DaVita's shares have gained 52.2%, outperforming the Medical - Outpatient and Home Healthcare sector's 16.8% rise, as well as the Zacks Medical sector's increase of 4.6% and the S&P 500's rise of 21.9% [6] - DaVita's forward 12-month price-to-earnings (P/E) ratio is 14.5X, which is a discount compared to the industry average of 21.2X and other industry players [7] Long-Term Outlook - DaVita is expected to maintain strong performance in 2024 due to investments in technology aimed at improving automation and claims processing [9] - The company is optimistic about its innovation track record and cost structure discipline, which are expected to enhance RPT growth [9] Investment Considerations - DaVita's core business strength, earnings potential, and global opportunities suggest favorable growth prospects, making it a consideration for existing investors [11] - The current valuation indicates potential for superior performance compared to industry peers, but the stock is still valued lower than the broader market, suggesting room for growth [11]